08:28 AM EST, 02/11/2025 (MT Newswires) -- Travere Therapeutics ( TVTX ) said Tuesday that it has completed a meeting with the US Food and Drug Administration and plans to submit a supplemental New Drug Application for approval of Filspari as a potential treatment for focal segmental glomerulosclerosis, a rare kidney disorder.

The application is based on the drug's mid-stage and late-stage studies and is expected to be submitted late in Q1, the company said.